Market News AIOpen the app

Verastem Oncology shares details from its earnings call for the second quarter of 2026.

ResultsRead the original at Benzinga
Good for VSTM

Verastem's product sales rebounded, and new cash and study progress support a stronger outlook. The full royalty amount and goal of covering costs by year-end 2026 are not yet assured.

VSTM · Verastem Oncology

AI read · Good for VSTM

The AI's read

Growing use of the drug combination and added cash give Verastem more room to advance its cancer studies. The royalty deal offers up to $75 million, with $50 million expected at closing, and Secura Bio paid a $15 million milestone. The goal of covering costs with sales by year-end 2026 is still a target, but the sales rebound and added cash support the more favorable read.

Get alerts for VSTM

Follow Verastem Oncology (VSTM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VSTM
Free on the App Store and Google Play, or on the web.